Supplier News: Alcami, Mikart, PharmaLogic & More 

The latest from CDMOs, CMOs, and suppliers featuring Alcami, Mikart, PharmaLogic, Ecolab, LTS, Ardena and Symeres.  

Chemicals/Chemical API Manufacturing 
PharmaLogic Opens New Radiopharmaceutical Mfg Facility 
Biologics Manufacturing 
Ecolab Opens New Bioprocessing Lab 
Formulation Development/Drug Product Manufacturing 
Mikart Opens New HQ, Expanding Mfg 
LTS Adds Ophthalmic Drug Delivery Services 
Packaging 
Alcami Completes Acquisition of Tjoapack 
Appointments 
Symeres Appoints New CEO 
* Ardena Appoints New CFO, CCO 


Chemicals/Chemical API Manufacturing 

PharmaLogic Opens New Radiopharmaceutical Mfg Facility 
PharmaLogic, a CDMO specializing in radiopharmaceuticals, has opened a new PET radiopharmaceutical manufacturing facility in Atlanta, Georgia, to expand its radiopharmaceutical production and research facilities. Equipped with PET manufacturing technology, the facility is designed to expand current production capacity while providing dedicated resources for the research and development of novel radiopharmaceuticals. 

Source: PharmaLogic 


Biologics Manufacturing 

Ecolab Opens New Bioprocessing Lab 
Ecolab Life Sciences has opened a new bioprocessing applications lab in Dongtan, Korea, its first bioprocessing facility in Asia. The lab supports process development activities from early-stage testing through studies that replicate manufacturing at scale. The site builds on Ecolab’s bioprocessing applications network in the US and UK. 

Source: Ecolab 


Formulation Development/Drug Product Manufacturing 

Mikart Opens New HQ, Expanding Mfg 
Mikart, a CDMO, has opened its new headquarters in northwest Atlanta. Originally announced in September 2025, the new space will serve as the company’s primary executive headquarters. 

In parallel with the headquarters move, Mikart is advancing a manufacturing expansion focused on oral solid dosage bottling and downstream packaging operations. This initiative will increase bottling capacity by more than 50%. The expansion project is scheduled for completion with operational start-up in the fourth quarter of 2026. 

Source: Mikart 


LTS Adds Ophthalmic Drug Delivery Services 
LTS Lohmann Therapie-Systeme AG, a pharmaceutical technology company specializing in drug-delivery systems, has announced the expansion of its service portfolio to include CDMO services for ophthalmic drug delivery, with manufacturing capacities in Lakewood, New Jersey. The new offering focuses initially on product development through clinical manufacturing of sterile ophthalmic products for filled-in preservative–free multidose devices.  

Source: LTS 


Packaging 

Alcami Completes Acquisition of Tjoapack 
Alcami, a CDMO of drug products and provider of analytical testing services, has completed its acquisition of Tjoapack, a contract packaging organization with facilities in the US and the Netherlands. Tjoapack’s packaging and labeling services include oral solid dose (blister and bottles), sterile injectables (vials, prefilled syringes and auto-injectors), and kitting. Tjoapack operates from facilities in Clinton, Tennessee, and Etten-Leur, the Netherlands, with 23 packaging lines. 

Source: Alcami 


Appointments 

Symeres Appoints New CEO 
Symeres, a Nijmegen, the Netherlands-based CDMO, has announced the appointment of Dr. Henning Steinhagen, currently CEO of Lario Therapeutics, as Chief Executive Officer.  

Dr. Steinhagen has more than 25 years of experience across the pharma, biotech and CRO/CDMO sectors. He joins from Lario Therapeutics, where he served as CEO and co-founder, as well as Venture Partner at Epidarex Capital. His previous positions include President of R&D at Aptuit, where he was a key member of the leadership team responsible for the company’s growth and successful sale to Evotec in 2017. Prior to that, he was Senior Vice President and Head of Global Drug Discovery at Grünenthal and held senior roles at Sanofi-Aventis and Bayer Pharma. 

Source: Symeres 


Ardena Appoints New CFO, CCO 
Ardena, a Ghent, Belgium-based CDMO of drug substances and drug products, has appointed Ben Ash, currently Chief Financial Officer at Essential Pharma, a bio/pharmaceutical company, as Chief Financial Officer, and Henny Zijlstra, currently Chief Commercial Officer at Adragos, a CDMO, as Chief Commercial Officer.  

Ash joins Ardena as Chief Financial Officer, bringing more than 20 years of finance leadership experience, predominantly within the pharmaceutical sector. He has held senior finance roles across publicly listed companies in the UK and US as well as privately held organizations, including most recently as Chief Financial Officer at Essential Pharma. Prior to this, he held senior finance roles at PTC Therapeutics and Shire. 

Zijlstra joins Ardena as Chief Commercial Officer. She has held senior leadership roles across the CDMO sector, including at Lonza, and most recently at Adragos. 

Source: Ardena